XERSXeris Biopharma Holdings, Inc.

$960M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+62.6% YoY

Gross Profit

$40M83.0% margin

Operating Income

-$5M-10.2% margin

Net Income

-$12M-25.2% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+27.1%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$328M

Total Liabilities

$324M

Stockholders' Equity

$4M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$30M	+62.6%
Gross Profit	$40M	$24M	+64.0%
Operating Income	-$5M	-$19M	+73.8%
Net Income	-$12M	-$22M	+44.2%

Revenue Segments

Product

$42M72%

Keveyis

$16M28%

XERS Q3 2023 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena